PDF(Pubmed)
Abstract：
Our objective was to provide consensus recommendations from a consortium of academic and industry experts in the field of lymphoma and imaging for consistent application of the Lugano classification. Methods: Consensus was obtained through a series of meetings from July 2019 until September 2021 sponsored by the Pharma Imaging Network for Therapeutics and Diagnostics (PINTaD) as part of the PINTaD Response Criteria in Lymphoma Working Group (PRoLoG) consensus initiative. Results: Consensus recommendations clarified technical considerations for PET/CT and diagnostic CT from the Lugano classification, including updating the FDG avidity of different lymphoma entities, clarifying the response nomenclature, and refining lesion classification and scoring, especially with regard to scores 4 and 5 and the X category of the 5-point scale. Combination of metabolic and anatomic responses is clarified, as well as response assessment in cases of discordant or missing evaluations. Use of clinical data in the classification, especially the requirement for bone marrow assessment, is further updated on the basis of lymphoma entities. Clarification is provided with regard to spleen and liver measurements and evaluation, as well as nodal response. Conclusion: Consensus recommendations are made to comprehensively address areas of inconsistency and ambiguity in the classification encountered during response evaluation by end users, and such guidance should be used as a companion to the 2014 Lugano classification.
摘要：
我们的目标是提供来自淋巴瘤和成像领域的学术和行业专家联盟的共识建议，以一致地应用Lugano分类。方法：共识是通过2019年7月至2021年9月由治疗和诊断药物成像网络（PINTaD）赞助的一系列会议获得的，作为淋巴瘤工作组（PRoLoG）共识计划的一部分。结果：共识建议从Lugano分类中阐明了PET/CT和诊断CT的技术考虑因素，包括更新不同淋巴瘤实体的FDG代谢，澄清响应命名法，并细化病变分类和评分，特别是关于分数4和5以及5分量表的X类别。代谢和解剖反应的组合是明确的，以及评估不一致或缺失的情况下的反应评估。在分类中使用临床数据，特别是骨髓评估的要求，在淋巴瘤实体的基础上进一步更新。提供了关于脾脏和肝脏测量和评估的澄清，以及节点响应。结论：提出了共识建议，以全面解决最终用户在响应评估过程中遇到的分类不一致和歧义的领域，这样的指导应该作为2014年卢加诺分类的配套。
